RxDoctor Payments Data

Orlando Fernando, MD

Internal Medicine · Baxley, GANPI 1982663381

Payments from drug & device makers

$741in general payments, 2019–2025

Across 46 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$223
  • Sanofi-aventis U.S. LLC$99
  • Pfizer$95
  • Novartis$64
  • Exact Sciences$44
  • Xeris Pharmaceuticals, Inc.$35
  • plus $181 from 9 others

What the payments were for

  • Food & beverage$72798%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$741 in reported general payments places this provider in the 60th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$2,137
Medicare patients
17
Services billed
29

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban356$95,036
OzempicSemaglutide77$83,341
Trelegy ElliptaFluticasone/Umeclidin/Vilanter87$68,069
JanuviaSitagliptin Phosphate151$64,838
RybelsusSemaglutide52$63,209
Tresiba Flextouch U-200Insulin Degludec38$41,467
XareltoRivaroxaban53$35,696
Tresiba Flextouch U-100Insulin Degludec37$25,337
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$24,117
MounjaroTirzepatide20$19,872
Breo ElliptaFluticasone/Vilanterol40$18,628
JardianceEmpagliflozin27$17,640
FarxigaDapagliflozin Propanediol67$16,732
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog30$10,653
LantusInsulin Glargine,hum.Rec.Anlog32$10,588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Fiasp$223$150,523144 claims
PfizerEliquis$95$95,036356 claims
AstraZenecaFarxiga, Bevespi Aerosphere, Symbicort$12$26,86192 claims
Lilly USA, LLCMounjaro$28$19,87220 claims
Boehringer IngelheimJardiance$14$17,64027 claims
Sanofi-aventis U.S. LLCLantus$99$10,58832 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Baxley

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →